Our flagship strategy
We invest in the most promising biopharmaceutical and medical device start-ups that address pressing unmet clinical needs and aim to transform patients’ lives.
Capital X, the 10th iteration of our flagship fund, is the largest healthcare fund dedicated to early-stage investments and company creation in Europe.
| Close | Fund | AMT |
|---|---|---|
| 2008 | Sofinnova Capital VI | €260 million |
| 2012 | Sofinnova Capital VII | €240 million |
| 2015 | Sofinnova Capital VIII | €300 million |
| 2018 | Sofinnova Capital IX | €333 million |
| 2021 | Sofinnova Capital X | €472 million |
Close: 2008
Fund: Sofinnova Capital VI
AMT: €260 million
Close: 2012
Fund: Sofinnova Capital VII
AMT: €240 million
Close: 2015
Fund: Sofinnova Capital VIII
AMT: €300 million
Close: 2018
Fund: Sofinnova Capital IX
AMT: €333 million
Close: 2021
Fund: Sofinnova Capital X
AMT: €472 million
“I've wanted to be in biotech since I was 16 years old. It was the early days, when Amgen and Genentech were first in the news, and it just sounded cool to me.”
“I joined Sofinnova Partners because first of all, they have a fantastic brand in Europe, but it's easy to see it is a very strong partnership. They're loyal to each other and everyone knows they treat entrepreneurs well.”
The
Team
Antoine Papiernik
Chairman & Managing Partner
Graziano Seghezzi
Managing Partner
Henrijette Richter
Managing Partner
Maina Bhaman
Partner, Capital Strategy
ZhiZhong (Joel) Yao
Principal, Capital Strategy
Anta Gkelou
Principal, Capital Strategy
Ankeet Jethwa
Associate, Capital Strategy
Marie Duranteau
Senior Analyst, Capital Strategy
Companies
Fund iteration
Status
Deal lead
Capital
Ablynx NV
Capital
Ascendis Pharma
Capital
Asceneuron
Capital
Avantium
Capital
Breath Therapeutics
Capital
Catamaran Bio
Capital
CinCor Pharma
Capital
CoreValve
Capital
CorVent Medical
Capital
Corvidia Therapeutics
Capital & MD Start
CorWave
Capital
Crescendo Biologics
Capital
DBV
Capital
Delinia
Capital
Enthera Pharmaceuticals
Capital
ENYO Pharma
Capital
EOS
Capital
EryDel
Capital & Telethon
GeneSpire
Capital
Genset
Capital
GlycoEra
Capital
GlycoVaxyn
Capital
HighLife
Capital
Home Biosciences
Capital
Hookipa Pharma
Capital
HotSpot Therapeutics
Capital
Innate Pharma
Capital
Inotrem
Capital
Inspirna
Capital
iOmx Therapeutics
Capital
Lysogene
Capital
Mablink Bioscience
Capital & Crossover
Mainstay Medical
Capital & MD Start
May Health
Capital
Mironid
Capital
Mission Therapeutics
Capital
Mnemo Therapeutics
Capital
Movetis
Capital
Mozart Therapeutics
Capital
Muna Therapeutics
Capital
Myricx Pharma
Capital
Nitrase Therapeutics
Capital
NodThera
Capital
Noema Pharma
Capital
Novexel
Capital
NuCana
Capital
ObsEva
Capital
Omthera Pharmaceuticals
Capital
Pi-Cardia
Capital
Pixium Vision
Capital
Polyneuron Pharmaceuticals
Capital
PregLem
Capital
ProQR Therapeutics
Capital
ReCor Medical
Capital
RefleXion Medical
Capital & MD Start
SafeHeal
Capital
Shockwave Medical
Capital
Sitryx Therapeutics
Capital
Tissium
Capital
Twentyeight-Seven Therapeutics
Capital
VectivBio
0 results
Related News
Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints
Noema Pharma receives FDA Fast Track designation for basimglurant (NOE-101) in trigeminal neuralgia
Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners
Inotrem announces positive outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide
Muna Therapeutics awarded $4.9M grant from The Michael J. Fox Foundation for Parkinson's research